Category Archives: Stell Cell Research

Guide to California’s Propositions on the 2020 Ballot – monroviaweekly

With the election date getting closer, it is important that Californians know what they are being asked to vote on. File photo by Terry Miller / Beacon Media News

By Destiny Torres

This years general election is right around the corner. As Nov. 3 grows nearer, voters must understand everything that will appear on their ballots.

There will be a total of 12 propositions for Californians to vote on this year. While it may be difficult to research all of them on ones own, these are all the ballot initiatives voters will be asked to decide on this election.

With this proposition, voters will be deciding on whether or not to issue $5.5 billion in state bonds to the California Institute for Regenerative Medicine (CIRM).

CIRM was created in 2004 after voters approved Proposition 71, the California Stem Cell and Research Initiative, to fund stem cell research along with issuing $3 billion in bonds. Proposition 71 also created a 29-member governing board to oversee the program; Proposition 14 would increase the number of members to 35.

Approving this initiative would increase state costs possibly over the next 30 years.

The approval of this measure would mean amending the states constitution to require that commercial and industrial properties be taxed according to market value rather than on the purchase price. Exempted from these changes are residential properties, agricultural land and owners of commercial and industrial properties whose value is less than $3 million.

Those opposed argue that the measure would repeal taxpayer protections provided by Proposition 13, an initiative approved in 1978 that stabilized state property taxes by capping it at a 2% increase per year.

But, as bad as that would be for the economy overall, split roll takes special aim at agriculture and would sweep across our farms and ranches like a wildfire, wrote Ted Gaines, a former state senator and member of the California State Board of Equalization wrote for Bakersfield.com.

Proposition 15 only applies to commercial and industrial properties, or holdings worth over $3 million.

Those who approve argue that larger companies should not be taxed the same way that homeowners or smaller businesses do.

Were asking for companies like Disneyland or Universal Studios that make huge amounts of money to pay property taxes based on fair market valuethe same thing that homeowners and, frankly, most businesses have to do, Josh Pechthalt, president of the California Federation of Teachers, told Rewire News Group.

The money from these new taxes would be dispersed in a very specific way rather than going to one general fund. The ballot initiative states that revenue from the new taxations would go to public schools, community colleges and local governments.

Proposition 209, or the Affirmative Action Initiative, is a measure approved in 1996 which amended the state constitution to prohibit public state institutions from considering race, sex, or ethnicity in areas of public employment, public education and public contracting, therefore banning the use of affirmative action.

Affirmative action is the practice of favoring individuals in certain groups that are known to have been historically discriminated against. It was used to ensure that minority groups had more access to public employment and schooling.

Proposition 16 would defeat Proposition 209. If approved, state and local governments, public schools and other public services would be allowed to use affirmative action policies that would grant access to people based on their race, sex and ethnicity.

Currently, the states constitution disqualifies people with felonies from voting until both their prison sentence and parole are completed.

Proposition 17 would amend that law by allowing people with felonies who have completed their prison sentence to vote while on parole.

A yes vote for this initiative would make it possible for 17-year-olds to vote in primary elections if they will be turning 18 by the time of the general election.

This ballot initiative targets the taxes of homeowners who are 55 or older, people with disabilities, or people who lost their homes to a natural disaster.

A yes vote on Proposition 19 would amend the states constitution to allow these homeowners to transfer their lower property taxes to their newer home if they choose to buy somewhere else in the state regardless of its market value, giving them a major tax break.

It also means that if someone were to inherit their home from a family member and later try to rent it out to Airbnb instead of using it as their primary home, they would receive a tax increase based on the homes present market value.

Additional money made from this value would go to firefighters and public schools.

A no vote means the law remains the same and property tax transfers can only occur if the market value is the same or higher of their previous home.

Proposition 20 would change many laws passed to reduce the states prison population.

Crimes like theft and fraud are currently charged as misdemeanors, Proposition 20 would change that so they are charged as felonies.

It would also make parole review boards look at other factors when determining whether or not non-violent felons should receive parole. These new elements would include age, skills and mental condition.

Along with these changes, the proposition would also require that convicted felons submit their DNA to the state and federal government databases.

A vote yes would increase the jail population leading to an estimated major increase in the states costs.

This proposition would allow local governments to establish rent control on properties that are over 15 years old.

If Proposition 22 were to be approved, drivers who work for apps like Uber, DoorDash and Lyft would be labeled as independent contractors. These app companies would then implement their own labor and wage policies, and not have to adhere to state labor laws such as providing minimum wage, unemployment insurance and workers compensation.

If the proposition is rejected, the government would be able to decide whether drivers are independent contractors or employees.

This proposition would require at least one licensed physician to be present at the clinic at all times unless there is a significant staff shortage. Without state approval, clinics would not be allowed to close or reduce services. Proposition 23 also prohibits clinicians to refuse care to patients based on their form of payment.

It would also require clinics to report newfound data to the state and the federal government.

With the digital age in full swing, many consumers have become worried about what businesses do with their private information like using it for marketing or advertising.

Proposition 24 would further protect consumers information by ensuring that businesses do not share private information upon the request of a consumer and giving people the ability to opt-out.

It also adds more protection for younger users like businesses would need to get permission before collecting information from people under 16 or gain permission from parents before collecting data from children under 13.

If a business were to violate any rules, this proposition also changes the possibility of businesses fixing their mistake before paying the price for it.

In California, a person who is arrested has the option of paying their bail or taking out a bail loan. Because of this, wealthier people can get out of jail right away without borrowing money or taking a plea deal.

This proposition would replace the cash bail system with an algorithm that would determine a criminals flight risk before their trial.

Read the rest here:
Guide to California's Propositions on the 2020 Ballot - monroviaweekly

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Development Trends & Competitive Analysis by Leading Industry Players – The…

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market is expected to exceed more than US$ 4.5 Billion by 2024 at a CAGR of 4% in the given forecast period.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the GE Healthcare, A&D Medical, Dragerwerk, Hill-Rom, and Philips Healthcare. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

You Can Find Full Report: https://www.marketresearchengine.com/autologous-stem-cell-and-non-stem-cell-based-therapies-market

Autologous stem-cell transplantation (also called autogenetic, autogenic, or autogenic stem-cell transplantation or auto-SCT) is that the autologous transplantation of stem cellswhich is, the uniform cells or stem cells (cells from which different styles of cells develop) area unit taken from someone, accumulated, and given back to an equivalent person later. Although its most frequently dead by means that of hematogenic vegetative cells (antecedent of cells that forms blood) in hematogenic stem cell transplantation, in some cases internal organ cells square measure used profitably to mend the damages because of heart attacks.

The scope of the report includes a detailed study of global and regional markets for Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market with the reasons given for variations in the growth of the industry in certain regions.

Reasons to Buy this Report:

1) Obtain the most up to date information available on all Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market

2) Identify growth segments and opportunities in the industry. 3) Facilitate decision making on the basis of strong historic and forecast Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market.

4) Assess your competitors refining portfolio and its evolution.

The major driving factors of Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market are as follows:

The restraining factors of Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market are as follows:

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market has been segmented as below:

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market is Segmented on the lines of Product Analysis, Application Analysis, End-User Analysis and Regional Analysis. By Product Analysis this market is segmented on the basis of BP monitoring devices, Pulmonary pressure monitoring devices and ICP monitoring devices. By Application Analysis this market is segmented on the basis of Treating neurodegenerative, Autoimmune, Cardiovascular disorders skin transplant, Oncology and Other.

By End-User Analysis this market is segmented on the basis of Hospitals Sector, ASCs Sector and Others Sectors. By Regional Analysis this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World.

This report provides:

1) An overview of the global market for Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market and related technologies. 2) Analyses of global market trends, with data from 2015, estimates for 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2024. 3) Identifications of new market opportunities and targeted promotional plans for using topical acne treatment Market. 4) Discussion of research and development, and the demand for new products and new applications. 5) Comprehensive company profiles of major players in the industry.

Request Sample Report from here: https://www.marketresearchengine.com/autologous-stem-cell-and-non-stem-cell-based-therapies-market

Table of Contents

1 INTRODUCTION

2 EXECUTIVE SUMMARY

3 AUTOLOGOUS STEM CELL & NON STEM SELL THERAPY -TECHNOLOGY LANDSCAPE ANALYSIS

4 AUTOLOGOUS STEM CELL & NON STEM SELL THERAPY TECHNOLOGY INVESTMENT POTENTIAL

4.1 INVESTMENT CLIMATE ASSESSMENT 4.1.1 INVESTOR NETWORKS 4.1.1.1 PUBLIC FUNDING BODIES 4.1.1.2 FUNDING/GRANTS FROM NGO ORGANIZATIONS 4.1.1.3 PRIVATE INVESTORS AND VENTURE CAPITAL FIRMS 4.1.1.4 INSIGHTS ON CURRENT AND FUTURE TECH-INVESTMENT TRENDS 4.1.1.5 INVESTOR INCLINATION AND PATTERNS 4.2 INVESTMENT OPPURTUNITIES 4.2.1 LICENSING AND ACQUISITION 4.2.2 ANALYSIS OF POTENTIAL APPLICATION AREAS FOR TECHNOLOGY INVESTMENT

5 AUTOLOGOUS STEM CELL MARKET LANDSCAPE ANALYSIS

6 AUTOLOGOUS STEM CELL & NON STEM SELL THERAPY TECHNOLOGY ADOPTION POTENTIAL AND DEVELOPMENT BY GEOGRAPHY

7 COMPETITIVE LANDSCAPE

8 PATENT ANALYSIS

9 TECHNOLOGY ANALYSIS AND ROAD MAPPING

10 ANALYST INSIGHTS AND RECOMMENDATIONS

11 COMPANY PROFILES

11.1 ANTRIA (CRO) (U.S.)

11.2 BIOHEART (U.S.)

11.3 BRAINSTORM CELL THERAPEUTICS (U.S.)

11.4 CYTORI (U.S.)

11.5 DENDREON CORPORATION (U.S.)

11.6 FIBROCELL (U.S.)

11.7 GENESIS BIOPHARMA (U.S.)

11.8 GEORGIA HEALTH SCIENCES UNIVERSITY (U.S.)

11.9 NEOSTEM (U.S.)

11.10 OPEXA THERAPEUTICS (U.S.)

11.11 ORGENESIS (U.S.)

11.12 REGENEXX (U.S.)

11.13 REGENEUS (AUSTRALIA)

11.14 TENGION (U.S.)

11.15 TIGENIX (BELGIUM)

11.16 VIRXSYS (U.S.)

Other Related Market Research Reports:

Asia-Pacific Chromatography Solvents Market is Forecast to Cross US$ 555. 5 Million By 2024

Antidiabetics Market is Projected to Reach USD 80.0 Billion By 2024

Antibacterial Drugs Market is Projected to Reach US$ 38 Billion By 2023

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

The rest is here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Development Trends & Competitive Analysis by Leading Industry Players - The...

Global Adipose Derived Stem Cell Therapy Market 2020 Industry Analysis, Growth Factors, Share, Opportunities and Forecast to 2025 – The Daily…

Global Adipose Derived Stem Cell Therapy Market 2020 by Company, Type and Application, Forecast to 2025 is the latest addition to the database of MarketsandResearch.biz which exhibits an easily comprehensible description of the global market. The report provides proficient and in-depth research on the market, focusing on the market landscape and its growth prospects over the coming years from 2020 to 2025. The report emphasizes market share, market demographics, size as well as valuation and voluminous growth rate. The research also includes a discussion of the key vendors operating in this global Adipose Derived Stem Cell Therapy market. The study shares details such as current trends of the market in conjunction with the geographical landscape, demand scope, remuneration scale, and growth graph of this vertical have also been included in this report.

The report covers an in-depth analysis of the key trends and emerging drivers of the market as well as market characteristics, competitive landscape, market size and growth, regional breakdown, and strategies for this market. The research analyzes revenue growth, product range, and pricing factors related to the global Adipose Derived Stem Cell Therapy market. The report sheds light on the competition matrix and shares a versatile understanding of various vital details comprising new product related developments that are adequately addressed and invested by leading players in the global market. Details about the competitive landscape, ensuring robust growth in the global market has been given in the report.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/89396

The major players covered in the market are: AlloCure, Mesoblast, Cellleris, Antria, Intrexon, Celgene Corporation, Tissue Genesis, Cytori Therapeutics, Corestem, Pluristem Therapeutics, Cyagen, BioRestorative Therapies, Lonza, Pluristem Therapeutics, Celltex Therapeutics Corporation, iXCells Biotechnologies

Scope of Market Report:

This report provides an analysis of the supply chain, import, and export control, and future influence on the industry. Detailed analysis of the market status, competition pattern, advantages, and disadvantages of enterprise products, industry development trends (2020-2025), regional industrial layout characteristics, industrial policy has also been included. From raw materials to end-users of this industry are analyzed, as well as the trends of product circulation and sales channels are presented.

On the basis of regional segmentation, the market is bifurcated into major regions of North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, etc.), Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa). The regional analysis further covers country-wise bifurcation of the market and key players.

On the basis of product type, we research the production, revenue, price, market share, and growth rate, primarily split into: Autologous Stem Cells, Allogeneic Stem Cells

For the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Adipose Derived Stem Cell Therapy market report for each application, including: Therapeutic Application, Research Application

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/89396/global-adipose-derived-stem-cell-therapy-market-2020-by-company-type-and-application-forecast-to-2025

Unraveling Report Offerings

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact Us Mark Stone Head of Business Development Phone: +1-201-465-4211 Email: [emailprotected] Web: http://www.marketsandresearch.biz

Read the original post:
Global Adipose Derived Stem Cell Therapy Market 2020 Industry Analysis, Growth Factors, Share, Opportunities and Forecast to 2025 - The Daily...

EV Biologics To Perform Specialized Analysis of EV Biopharmaceuticals at Vanderbilt University – BioSpace

CHEYENNE, WY / ACCESSWIRE / September 29, 2020 / EV Biologics, Inc. formerly Yulong Eco-Materials Limited (OTC PINK:YECO) today announced that it intends to utilize the advanced instrumentation and research staff at the Vanderbilt Institute of Nanoscale Science and Engineering (VINSE) and the Vanderbilt Center for Structural Biology (CSB) in the development of extracellular vesicle (EV)-based diagnostics and therapeutics.

Founded in 1873, Vanderbilt University located in Nashville, Tennessee is a pre-eminent and legendary private research university comprised of 10 distinct schools and colleges on one centralized campus. Regularly ranked as one of the nation's top 15 universities by publications such as "U.S. News & World Report", with programs that rank in the top 10, Vanderbilt is a world-class institution. The University was recently ranked #10 in Reuter's assessment of the World's Most Innovative Universities. (Source: Vanderbilt University Website - https://www.vanderbilt.edu/csb).

Quality Control (QA/QC) is the cornerstone of the Company's plan for Current Good Manufacturing Practices cGMP development of EV diagnostics and therapeutic products. The Vanderbilt CSB and VINSE are extraordinary research facilities that have the capability of performing nanoscale analytical methods such as Atomic Force Microscopy, Electron Microscopy and Nano Tracking Analysis. The Vanderbilt University research staff has extensive experience with nanoparticle characterization methods that will form an essential part of QA/QC for the Company's therapeutic development.

The Company is making a significant investment in its own analytical equipment to facilitate novel solutions to overcome the challenges in EV product characterization and standardization. EV analysis performed by research staff at Vanderbilt will complement and confirm the Company's own EV development data and will provide the orthogonal characterization for EV research recommended by the International Society for Extracellular Vesicles.

CMO, Dr. Jason Sanders, said "having access to this kind of extremely specialized instrumentation and experts in nanoparticle analysis at such a highly respected institution as Vanderbilt will be instrumental in advancing our R&D program for biopharmaceuticals and will enable meticulous analysis for preparation of Investigational New Drug applications (IND's) to the FDA for maximum efficiency in EV drug development."

The Company is currently in the process of getting a new trading symbol with FINRA after successfully getting our name changed. Our goal is to become current in our OTC filings by the end of October with OTC Markets

About the Company

EV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, intent on bringing human mesenchymal "MSC" and other stem cell and cell-derived products to market in the cosmetic and biopharmaceutical spaces. Initially, these novel and unique products will be specifically provided to the international clinical research community including universities and physicians and will be targeted to the aesthetic and regenerative medicine markets. Using proprietary and patentable technologies, the Company is creating exclusive IP and IT inherent in our superior products. Further product development will be focused on investigation of novel stem cell-derived biopharmaceuticals designed for specific clinical conditions.

Forward-Looking Statements

This press release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company's financial position and business strategy. The words or phrases "plans," "would be," "will allow," "intends to," "may result," "are expected to," "will continue," "anticipates," "expects," "estimate," "project," "indicate," "could," "potentially," "should," "believe," "think," "considers" or similar expressions are intended to identify "forward-looking statements." These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

YECO has 6.21 million shares issued and outstanding with a float of 1,016,375 shares.

Contact:

Dennis Burns Investor Relations Tel(567)237-4132 dburns@nvestrain.com

For more information on EV Biologics please visit: http://www.evbiologics.com

SOURCE: Yulong Eco-Materials Limited

View source version on accesswire.com: https://www.accesswire.com/608226/EV-Biologics-To-Perform-Specialized-Analysis-of-EV-Biopharmaceuticals-at-Vanderbilt-University

Go here to read the rest:
EV Biologics To Perform Specialized Analysis of EV Biopharmaceuticals at Vanderbilt University - BioSpace

STEM CELL BANKING Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 – The Daily Chronicle

Fort Collins, Colorado The STEM CELL BANKING Market is growing at a rapid pace and contributes significantly to the global economy in terms of turnover, growth rate, sales, market share and size. The STEM CELL BANKING Market Report is a comprehensive research paper that provides readers with valuable information to understand the basics of the STEM CELL BANKING Report. The report describes business strategies, market needs, dominant market players and a futuristic view of the market.

The report has been updated to reflect the most recent economic scenario and market size regarding the ongoing COVID-19 pandemic. The report looks at the growth outlook as well as current and futuristic earnings expectations in a post-COVID scenario. The report also covers changing market trends and dynamics as a result of the pandemic and provides an accurate analysis of the impact of the crisis on the market as a whole.

Global STEM CELL BANKING Market to reach USD 11.2 billion by 2025. Global STEM CELL BANKING Market valued approximately USD 5.4 billion in 2016 is anticipated to grow with a healthy growth rate of more than 8.4% over the forecast period 2017-2025.

Get a sample of the report @ https://reportsglobe.com/download-sample/?rid=5214

Industry STEM CELL BANKING Study provides an in-depth analysis of key market drivers, opportunities, challenges and their impact on market performance. The report also highlights technological advancements and product developments that drive market needs.

The report contains a detailed analysis of the major players in the market, as well as their business overview, expansion plans and strategies. Key players explored in the report include:

The report provides comprehensive analysis in an organized manner in the form of tables, graphs, charts, pictures and diagrams. Organized data paves the way for research and exploration of current and future market outlooks.

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=5214

The report provides comprehensive data on the STEM CELL BANKING market and its trends to help the reader formulate solutions to accelerate business growth. The report provides a comprehensive overview of the economic scenario of the market, as well as its benefits and limitations.

The STEM CELL BANKING Market Report includes production chain analysis and value chain analysis to provide a comprehensive picture of the STEM CELL BANKING market. The research consists of market analysis and detailed analysis of application segments, product types, market size, growth rates, and current and emerging industry trends.

By Application:

Request customization of the report @https://reportsglobe.com/need-customization/?rid=5214

The market is geographically spread across several key geographic regions and the report includes regional analysis as well as production, consumption, revenue and market share in these regions for the 2020-2027 forecast period. Regions include North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

Radical Coverage of the STEM CELL BANKING Market:

Key Questions Addressed in the Report:

To learn more about the report, visit @ https://reportsglobe.com/product/global-stem-cell-banking-market-size-study/

Thanks for reading our report. It is possible to adapt this report to the wishes of the customer. Contact us to learn more about the report and our team will make sure you create a report based on your needs.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

See the rest here:
STEM CELL BANKING Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 - The Daily Chronicle

JAMA Oncology Highlights Plinabulin’s Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy – GlobeNewswire

September 29, 2020 08:00 ET | Source: BeyondSpring, Inc.

NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the Company or BeyondSpring) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology therapies to transform the lives of patients with unmet medical needs, today announced that the Companys manuscript, titled Efficacy of Plinabulin vs. Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer, has been published in JAMA Oncology, the American Medical Associations peer-reviewed journal.

The manuscript analyzed BeyondSprings Phase 2 portion of its PROTECTIVE-1 (Study 105) randomized clinical trial, which consisted of four treatment arms and was conducted in 19 treatment centers in the U.S., China, Russia and Ukraine from April 2017 through March 2018, with Covance serving as its contract research organization. Key primary and secondary endpoints were calculated using objective data, such as the absolute neutrophil count and platelet counts, which were based on validated assays conducted at Covances central labs in three continents. Participants were adult patients with non-small cell lung cancer (NSCLC) whose cancer had progressed after platinum-based chemotherapy. The objective was to assess the efficacy and safety of the Companys lead asset, Plinabulin, compared with Pegfilgrastim, a long-lasting G-CSF, which is currently the predominant therapy for chemotherapy-induced neutropenia (CIN) prevention.

The protocols were as follows:

Key results included:

The data presented demonstrates that Plinabulin a novel, non-G-CSF small molecule with anticancer activity has potent neutropenia prevention effects, said Dr. Douglas Blayney, Principal Investigator of BeyondSprings CIN program with Plinabulin. The results show the promise that Plinabulin has to deliver relief to cancer patients suffering around the world.

The results of this study validate Plinabulins strength and its potent ability to prevent CIN in cancer patients, added Dr. Ramon Mohanlal, BeyondSprings Chief Medical Officer and Executive Vice President, Research and Development. This study, coupled with the breakthrough designation granted to our CIN program from boththeU.S. FDAand China NMPA,is highly encouraging for our pending New Drug Application filings in bothcountries.

To access the full e-publication, please visit: https://jamanetwork.com/journals/jamaoncology/article-abstract/2770700.

About BeyondSpring Headquartered in New York, BeyondSpring is a global, clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to improve clinical outcomes for patients with high unmet medical needs. BeyondSprings first-in-class lead immune asset, Plinabulin, is a potent antigen-presenting cell (APC) inducer. It is currently in two Phase 3 clinical trials for two severely unmet medical needs indications: one is for the prevention of chemotherapy-induced neutropenia (CIN), the most frequent cause for a chemotherapy regimen doses decrease, delay, downgrade or discontinuation, which can lead to suboptimal clinical outcomes. The other is for non-small cell lung cancer (NSCLC) treatment in EGFR wild-type patients. As a pipeline drug, Plinabulin is in various I/O combination studies to boost PD-1 / PD-L1 antibody anti-cancer effects. In addition to Plinabulin, BeyondSprings extensive pipeline includes three pre-clinical immuno-oncology assets and a drug discovery platform dubbed molecular glue that uses the protein degradation pathway.

About Plinabulin Plinabulin, BeyondSprings lead asset, is a differentiated immune and stem cell modulator. Plinabulin is currently in late-stage clinical development to increase overall survival in cancer patients, as well as to alleviate chemotherapy-induced neutropenia (CIN). The durable anticancer benefits of Plinabulin have been associated with its effect as a potent antigen-presenting cell (APC) inducer (through dendritic cell maturation) and T-cell activation (Chem and Cell Reports, 2019). Plinabulins CIN data highlights the ability to boost the number of hematopoietic stem / progenitor cells (HSPCs), or lineage-/cKit+/Sca1+ (LSK) cells in mice. Effects on HSPCs could explain the ability of Plinabulin to not only treat CIN but also to reduce chemotherapy-induced thrombocytopenia and increase circulating CD34+ cells in patients.

Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company's future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSprings most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Media Contacts Caitlin Kasunich / Raquel Cona KCSA Strategic Communications ckasunich@kcsa.com / rcona@kcsa.com

Read the rest here:
JAMA Oncology Highlights Plinabulin's Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy - GlobeNewswire

Research Report and Overview on Stem Cell Cryopreservation Equipments Market, 2020-2027 with , Chart, Worthington Industries, Cesca Therapeutics,…

(September 2020):WMRsLatest Study on Stem Cell Cryopreservation Equipments Market report 2020-2027 providesan Overview of the current market situation,competitive analysis, product scope, market research, opportunities, driving force, and market risks. The report contains market forecast to 2027 related to market size, Consumption, gross margin, price,revenue, production, CAGR and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.

The Stem Cell Cryopreservation Equipments market report provides a basic overview of the industry, including definitions, classifications, applications, and chain structures. Stem Cell Cryopreservation Equipments market analysis is provided to international markets, including development trends, competitive environment analysis, and key regions development status.

Get the FREE Report Sample (Includes- Keyplayers Profiles, Table and Figures, ToC):https://www.worldwidemarketreports.com/sample/299689

Stem Cell Cryopreservation Equipments Market Segments Analysis Covers;

The major manufacturers covered in this report: , Chart, Worthington Industries, Cesca Therapeutics, Shengjie Cryogenic Equipment, Sichuan Mountain Vertical, Qingdao Beol,

Considering keyword Market factors, Types Covers: Liquid Phase, Vapor Phase,

Application Covers: Cord Blood Stem Cell Cryopreservation, Other Stem Cell Cryopreservation

Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; emergency declared in many countries; massive slowing of the supply chain; stock market unpredictability; falling business assurance, growing panic among the population, and uncertainty about future.

COVID-19 can affect the global Stem Cell Cryopreservation Equipments economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Get the Free Analysis on Coivd-19with Report, here you can ask for the Structured Report:https://www.worldwidemarketreports.com/covidimpact/299689

Table of Content (TOC) of Stem Cell Cryopreservation Equipments Market 2020:Chapter 1 Introduction and Overview Chapter 2 Industry Cost Structure and Economic Impact Chapter 3 Rising Trends and New Technologies with Major key players Chapter 4 Global Stem Cell Cryopreservation Equipments Market Analysis, Trends, Growth Factor Chapter 5 Stem Cell Cryopreservation Equipments Market Application and Business with Potential Analysis Chapter 6 Global Stem Cell Cryopreservation Equipments Market Segment, Type, Application Chapter 7 Global Stem Cell Cryopreservation Equipments Market Analysis (by Application, Type, End-User) Chapter 8 Major Key Vendors Analysis of Stem Cell Cryopreservation Equipments Market Chapter 9 Development Trend of Analysis Chapter 10 Covid-19 Analysis Chapter 10 Conclusion

Any quiry or Customization in ToC, place hre:https://www.worldwidemarketreports.com/quiry/299689

Benefits of buying Overbed Table Market Report:

Else, Contact Us:

Mr. Shah Worldwide Market Reports Seattle, WA 98154, U.S. Email: [emailprotected]

Here is the original post:
Research Report and Overview on Stem Cell Cryopreservation Equipments Market, 2020-2027 with , Chart, Worthington Industries, Cesca Therapeutics,...

Singapore inks research collaboration with India for biotherapeutics – BSA bureau

Manipal Academy of Higher Education (MAHE) in India and Esco Aster in Singapore have signed agreement to establish collaborative research unit at MAHE, Manipal

This is the second Esco Aster collaborative research unit set up globally after the firstCentre of Excellence (COE) with Bioprocessing Technology Institute (BTI), Singapore. Esco Aster hopes to continue to develop more collaborations in Asia Pacific in years to come to work on the booming cell and gene therapy.

As per the agreement, ESCO Aster and MAHE will jointly establish a research unit at MAHE Manipal campus to carry outactivities related to development and manufacturing in the biotherapeutics area.MAHE will provide cGMP compliant facility and necessary resources for carrying out the research activities.

-Lt. General Dr. Venkatesh M.D., MAHEs Vice Chancellor

Weare excited to sign this agreement with MAHE and we look forward for harnessing the skilled manpower and mentor pool available at MAHE to build our pipeline products and services to our clients. We envision showcasing this research unit to our potential clients and collaborators and also utilizing it as a training centre.

-Xiangliang Lin, Esco Aster Chief Executive Officer

Through this agreement, both parties aim to facilitate research, development, and commercial plans and activities relating to stem cells or extracellular vesicles. Other fields of study with potential advantages to scientific discoveries are also welcome. This collaboration opens up potential breakthrough discoveries aiming to drive the biotherapeutics industry.

Read this article:
Singapore inks research collaboration with India for biotherapeutics - BSA bureau

Orgenesis Announces Agreement to Acquire Koligo Therapeutics, a Leader in Personalized Cell Therapies – GlobeNewswire

September 29, 2020 06:30 ET | Source: Orgenesis Inc.

Acquisition to support accelerated commercialization of Koligos KYSLECEL,a personalized islet cell therapy available in the U.S. for chronic and recurrent acute pancreatitis

Goal to rapidly advance KT-PC-301, an autologous cell therapy under investigationfor the treatment of COVID-19-related Acute Respiratory Disease Syndrome (ARDS)

Orgenesis to leverage Koligos 3D-V bioprinting technology across its POCare Platform

GERMANTOWN, Md., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (Orgenesis or the Company), a global biotech company working to unlock the full potential of cell and gene therapies, and Koligo Therapeutics, Inc. (Koligo), a regenerative medicine company, today announced that the two companies have entered into a definitive merger agreement, subject to final closing conditions, with expected completion before year-end (Transaction).

Koligo is a leader in developing personalized cell therapies utilizing the patients own (autologous) cells. Koligo has successfully launched its first commercial product, KYSLECEL, and plans to commence a phase 2 trial of KT-PC-301 for COVID-19-related ARDS. Koligos development stage technology utilizes 3D bioprinting and vascularization with autologous cells (3D-V technology) to create biodegradable and shelf-stable three-dimensional cell and tissue implants. The 3D-V technology is being developed for diabetes and pancreatitis, with longer term applications for neural, liver, and other cell/tissue transplants.

Following closing of the Transaction, Orgenesis plans to accelerate the commercial scaleup of KYSLECEL throughout the United States and, subject to regulatory and logistical considerations, in international markets as well. After closing of the Transaction, and subject to FDA review and clearance of the Companys Investigational New Drug application, Orgenesis expects to start patient recruitment for a phase 2 randomized clinical trial of KT-PC-301 in COVID-19 patients. Orgenesis also plans to leverage Koligos 3D-V bioprinting technology across its POCare platform.

Under the terms of the merger agreement, Orgenesis will acquire all of the outstanding stock of Koligo from its shareholders (the founders and staff of Koligo and a subsidiary of Bergen Special Opportunity Fund, LP, an institutional investor managed by Bergen Asset Management, LLC). The agreed consideration terms are an aggregate of $15 million in shares of Orgenesis common stock valued at $7.00 per share which shall be issued to Koligos accredited investors (with certain non-accredited investors to be paid solely in cash) and an assumption of $1.3 million in Koligos liabilities, estimated to be substantially all of Koligos liabilities. Additional details of the Transaction will be available in the Companys Form 8-K, which will be filed with the Securities and Exchange Commission, and will be available at http://www.sec.gov.

KYSLECEL Koligos KYSLECEL is commercially available in the United States for chronic and recurrent acute pancreatitis in a surgical procedure commonly called Total Pancreatectomy with Islet Autologous-Transplant (TPIAT). TPIAT has been proven to provide significant pain relief, improved quality of life, and a reduction in the need for pain medication for patients suffering from chronic or recurrent acute pancreatitis. KYSLECEL infusion after a total pancreatectomy helps preserve insulin secretory capacity and reduce the risk of diabetic complications. KYSLECEL is made from a patients own pancreatic islets the cells that make insulin to regulate blood sugar.

Koligo has commenced its commercial pilot program for KYSLECEL at six U.S. hospitals, treating 40 patients to date. The KYSLECEL pilot program has generated approximately $2 million in sales revenue. KYSLECEL has also been shown to result in significant savings to payors over traditional chronic pancreatitis management. Following the closing of the Transaction, Orgenesis plans to make KYSLECEL available to an increasing number of hospitals throughout the United States through its POCare Network.

KT-PC-301 Koligos lead clinical development program is for KT-PC-301, an autologous cell therapy under investigation for the treatment of COVID-19-related Acute Respiratory Disease Syndrome (ARDS). KT-PC-301 is comprised of autologous stromal and vascular fraction cells (SVF) derived from each patients adipose (fat) tissue. KT-PC-301 contains a population of mesenchymal stem cells, vascular endothelial cells, and immune cells which migrate to the patients lungs and other peripheral sites of inflammation. Nonclinical and clinical evidence demonstrate that KT-PC-301 may: (1) stabilize microcirculation to improve oxygenation; (2) maintain T and B lymphocytes to support antibody production; and (3) induce an anti-inflammatory effect.

Koligo has completed a pre-IND (Investigational New Drug) consultation with the U.S. Food and Drug Administration to start clinical trials of KT-PC-301 in COVID-19-related ARDS. Following the closing of the Transaction, and subject to FDA review and clearance of the Companys Investigational New Drug application, Orgenesis expects to start patient recruitment for a phase 2 randomized clinical trial of KT-PC-301 in COVID-19 patients. As currently planned, the phase 2 trial is expected to enroll 75 patients and evaluate the safety and efficacy of KT-PC-301. Mohamed Saad, MD, Chief of Division of Pulmonary, Critical Care, and Sleep Disorders Medicine at the University of Louisville, will be the lead clinical investigator on the trial.

3D-V Technology Koligos 3D-V bioprinting technology is designed to support development of a number of product candidates for the treatment of diabetes, cancer, neurodegenerative disease, and other serious diseases. The 3D-V technology platform is able to print three-dimensional cell and tissue constructs with a vascular network. Key benefits of the 3D-V approach include: faster revascularization/inosculation of cell/tissue transplant to improve engraftment; host tolerance of the graft while minimizing need for immune suppressive drugs; better site of transplant administration of such products; and scaffolding to keep cell/tissue in place in vivo. These solutions are ideally suited for islet transplant and other cell/tissue transplant applications.

Koligo Management Following the closing of the Transaction, Koligos management team will be joining Orgenesis to continue commercial and development activities. Koligos CEO, Matthew Lehman, is an accomplished executive in the biotech and regenerative medicine fields. Prior to co-founding Koligo, he was CEO of Prima Biomed Ltd (now Immutep Ltd, a Nasdaq (IMMP) and ASX (IMM) listed biotech company). Stuart Williams, PhD, Chief Technology Officer, is a bioengineer and thought leader in regenerative medicine, with over 300 publications and 20 issued patents in the field. Dr. Williams has co-founded three other biotech companies and is an experienced academic-industry collaborator. Michael Hughes, MD, Chief Medical Officer, is a transplant surgeon who started the islet transplant program at University of Louisville which was the genesis of Koligos KYSLECEL program. He has successfully treated nearly 50 chronic pancreatitis patients with islet autologous transplant after pancreatectomy. Balamurugan Appakalai, PhD, has more than 20 years of islet isolation experience, having processed more than 800 human pancreases. He is a leader in the field of islet transplant with 100+ publications.

Vered Caplan, Chief Executive Officer of Orgenesis, stated, We are pleased to announce this transformative acquisition, which we expect will add broad capabilities to our therapeutic and technology platform, and will further our leadership in the cell and gene therapy field. Based on several phase 1 studies, Koligos KT-PC-301, using a patients own cells, has demonstrated safety and tolerability, and has shown signs of efficacy to support continued development in COVID-19-related ARDS. If successful for the treatment of COVID-19-related ARDS, KT-PC-301 is likely to have applications in other acute and chronic respiratory indications, areas that represent significant unmet medical need. In addition, we see significant potential in KYSLECEL, a commercial stage asset for the treatment of chronic and acute recurrent pancreatitis, which we plan to introduce through our global network of hospitals. Finally, Koligos 3D-V bioprinting technology is highly complementary to our POCare Platform, as we implement new technologies to improve efficacy and lower the costs of cell and gene therapies. I would like to personally welcome Matthew and the rest of the Koligo team to the Orgenesis organization when the Transaction closes. We believe that their skills and experience will be an important addition as we execute on our strategy to unlock the power of cell and gene therapies and make them accessible to all.

Matthew Lehman, Chief Executive Officer of Koligo Therapeutics, stated, The merger with Orgenesis marks a major milestone for our company and builds on our recent progress, including the Pre-IND package submitted to the U.S. FDA for KT-PC-301 and our pilot commercial program for KYSLECEL. The Orgenesis team brings extensive clinical, regulatory, and manufacturing expertise well suited to supporting Koligos goals. Orgenesis intellectual property is highly complementary to Koligos technology and the combined companies will work to advance a robust commercial and development product portfolio. Orgenesis POCare technologies are also ideally suited for low-cost and efficient production of autologous cell therapies at the point of care, which we believe will considerably enhance the delivery of these therapies to patients. Additionally, we believe Orgenesis global network of leading hospitals and healthcare institutions will enable us to accelerate the commercial rollout of KYSLECEL. We are quite encouraged by the outlook for the business and look forward to leveraging Orgenesis POCare Platform in order to accelerate the timeline to bringing our innovative cell therapies to market. Through this merger, we believe we can maximize value for all shareholders and we are grateful to Orgenesis for this opportunity.

Pearl Cohen Zedek Latzer Baratz LLP and KPMG advised Orgenesis on the Transaction. Maxim Group LLC acted as a finder and Nelson Mullins Riley & Scarborough, LLP advised Koligo on the Transaction.

About Koligo Therapeutics Koligo Therapeutics, Inc. is a US regenerative medicine company. Koligos first commercial product is KYSLECEL (autologous pancreatic islets) for chronic and acute recurrent pancreatitis. Koligos 3D-V technology platform incorporates the use of advanced 3D bioprinting techniques and vascular endothelial cells to support development of transformational cell and tissue products for serious diseases. More information is available at http://www.koligo.net.

About OrgenesisOrgenesis is a global biotech company working to unlock the full potential of celland gene therapies (CGTs) in an affordable and accessible format at the point of care. The Orgenesis POCarePlatform is comprised of three enabling components: a pipeline of licensedPOCare Therapeuticsthat are processed and produced in closed, automatedPOCare Technologysystems across a collaborativePOCare Network. Orgenesisidentifies promising new therapies and leverages its POCare Platform to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production. The Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide to achieve harmonized, regulated clinical development and production of the therapies. Learn more about the work Orgenesis is doing atwww.orgenesis.com.

Notice Regarding Forward-Looking Statements The information in this release is as of September 29, 2020. Orgenesis assumes no obligation to update forward-looking statements contained in this release as a result of new information or future events or developments. This release contains forward looking statements about Orgenesis, Koligo, Koligos technology, and potential development and business opportunities of Koligo and Orgenesis following the closing of the Transaction, each of which involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of the Companys products; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any such regulatory authorities may approved the Companys development products, and, if approved, whether such product candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of the Companys products; uncertainties regarding the impact of COVID-19 on the Companys business, operations and financial results and competitive developments.

A further description of risks and uncertainties can be found in the Companys Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned Risk Factors and Forward-Looking Information, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at http://www.sec.gov.

Contact for Orgenesis: Crescendo Communications, LLC Tel: 212-671-1021 ORGS@crescendo-ir.com

More here:
Orgenesis Announces Agreement to Acquire Koligo Therapeutics, a Leader in Personalized Cell Therapies - GlobeNewswire

Whats on Your Local Ballot? – City News Group, Inc

On Monday October 5, 2020 early voting begins at the Registrar of Voters and mail ballots are delivered to the U.S. Postal Service- increasing the already present deadline for Election Day on November 3, 2020.

With early voting in full swing, the consumption of information on candidates and legislature is paramount. Knowing who and what will be on your ballot before Election Day, may provide you the time to get to know the people and legislature that impacts our community and day-to-day lives before you cast your vote. Get to know what California Propositions, County and City Measures are on your ballot this fall.

CountyofSanBernardinoMeasures

MeasureJ:

REVISEDCHARTEROFTHECOUNTYOFSANBERNARDINO

*Information for "Arguments in Favor" and "Arguments Against" is from the official arguments section on the voters ballot*

Argument in Favor:

San Bernardino County's charter - the laws that govern our community - was written more than 100 years ago. It's time to modernize our charter. Measure J will:

Argument Against:

Don't be fooled. This charter "reform" is not reform. It's a way for the county board of supervisors to lock out voters when it comes to decisions about term limits and compensation. Since elected Supervisors collect a salary of over $250,000 annually nearly six-times the median income of San Bernardino residents and can serve twelve long years, it's easy to understand their motives.

MeasureK

SANBERNARDINOCOUNTYSUPERVISORCOMPENSATIONREDUCTIONANDTERMLIMITS. This Measure would amend the San Bernardino County Charter provisions relating to the term limits and compensation of the members of the Board of Supervisors. San Bernardino County Charter Article I, Section 2 would be amended to impose a term limit of one-term for each Supervisor. The Measure would add Section 10 to Article I of the San Bernardino County Charter to set the total compensation for each member of the Board of Supervisors at $5,000 per month and would repeal San Bernardino County Charter Article VI, Section 1 that currently sets compensation for members of the Board of Supervisors.

Argument in Favor:

Voting YES for term limits and reduced salaries will finally attract representatives interested in public service and committed to following the will of the people.

Argument Against:

Measure K will result is less representation for residents of San Bernardino County on the Board of Supervisors. We need more representation, not less.

CityofSanBernardinoMeasure S:

TopreventreductionstoCityservicesincludingpublicsafety,911emergencyresponse,Currently, the City has a one-quarter percent (1/4%) retail transactions and use (sales) tax, that generates approximately $9 million annually. The current tax expires on March 31, 2022. If this Measure is approved by a majority of San Bernardino voters, this Measure would authorize an increase of the retail transactions and use (sales) tax from one-quarter percent (1/4%) to one percent (1%) within the City of San Bernardino.

Argument in Favor:

Vote YES on Measure S to provide a brighter future for San Bernardino. Measure S renews a critical source of local funding, prevents further cuts to essential city services, improves 911 emergency response, and protects local businesses and jobs here in San Bernardino

Argument Against:

No Argument Against Measure S was filed.

SanBernardinoCountyFireProtectionDistrictMeasure U

This Measure, if approved by a majority of those voting, would repeal the special tax associated with Fire Protection Service Zone Five (FP-5). County Service Area (CSA) 70, Improvement Zone FP-5 was formed on April 18, 2006. On August 1, 2006, a special tax was authorized following a two-thirds vote of registered voters in CSA 70, Improvement Zone FP-5 for fire and emergency medical services. The previously authorized special tax per parcel remained in effect in the reorganized FP-5. Over time, FP-5 has been expanded to include some cities and unincorporated territory in the County of San Bernardino.

Argument in Favor:

VOTE YES on Measure U to END THE UNFAIR FIRE TAX! Beginning in 2015, to save themselves money, politicians across San Bernardino County traded away local fire protection and joined a large, regional agency, saddling residents with a tax increase that penalizes poor and middle-class families the same as rich corporate property owners. This tax approved by only a small number of people, impacts over a million San Bernardino residents. In fact, over 99% of those impacted never had the chance to vote on dismantling local fire protection or paying a new tax!

Argument Against:

VOTE NO on Measure U Measure U is a DANGEROUS PROPOSAL to DEFUND FIRE PROTECTION services for residents in the communities served by the San Bernardino County Fire Protection District. Measure U ELIMINATES $40 MILLION in funding for Emergency Medical and Fire Protection services. It cuts essential life-saving services not budgetary fat. By REDUCING PARAMEDIC SERVICES, Measure U will WORSEN response times in life-threating medical emergencies putting our families at greater risk.

California State Propositions:

Proposition 14: AUTHORIZES BONDS CONTINUING STEM CELL RESEARCH. INITIATIVE STATUTE.

Authorizes $5.5 billion in state general obligation bonds to fund grants from the California Institute of Regenerative Medicine to educational, nonprofit, and private entities for: stem cell and other medical research, including training; stem cell therapy development and delivery; research facility construction; and associated administrative expenses. Increased state costs to repay bonds estimated at about $260 million per year over the next roughly 30 years.

Argument in Favor:

Prop. 14 provides continued funding to develop treatments, advance clinical trials and achieve new scientific breakthroughs for Californias patients with Cancer, Diabetes, Heart Disease, Alzheimers, Parkinsons, HIV/AIDS, ALS, MS, Sickle Cell Disease, Lung Diseases, Kidney Disease, Bubble Baby Disease, Age-Related Blindness and Genetic Blindness, Epilepsy, Stroke, Schizophrenia, Autism, other Mental Health and Brain Conditions, and Infectious Diseases like COVID-19.

Argument Against:

WE CANT AFFORD TO WASTE BILLIONS In the middle of an economic crisis, with soaring unemployment and budget shortfalls in the tens of billions of dollars, we dont have money to burn. We simply cannot afford the $5 billion that proponents of Prop. 14 are asking for. And thats on top of the nearly $3 billion this troubled state agency has spent over the past 15 yearswith poor results.

Proposition15: INCREASES FUNDING SOURCES FOR PUBLIC SCHOOLS COMMUNITY COLLEGES, AND LOCAL GOVERNMENT SERVICES BY CHANGING TAX ASSESSMENT OF COMMERCIAL AND INDUSTRIAL PROPERTY. INITIATIVE CONSTITUTIONAL AMENDMENT.

Increases funding sources for K12 public schools, community colleges, and local governments by requiring commercial and industrial real property be taxed based on current market value, instead of purchase price. Exempts from taxation changes: residential properties; agricultural land; and owners of commercial and industrial properties with combined value of $3 million or less.

Most owners of commercial land and buildings worth more than $3 million would pay higher property taxes. Only some of these property owners would start to pay higher taxes in 2022. By 2025, most of these property owners would pay higher taxes. Beginning in 2025, total property taxes from commercial land and buildings probably would be $8 billion to $12.5 billion higher in most years

Argument in Favor:

We are all better off when everyone pays their fair share. But California is giving away billions of dollars in property tax breaks to wealthy corporations. These billions could be used instead to deal with increasing inequality, persistent poverty, unemployment, unaffordable housing, homelessness and underfunded schools.

Argument Against:

PROP. 15 WILL BE THE LARGEST ANNUAL PROPERTY TAX INCREASE IN CALIFORNIA HISTORYUP TO $12.5 BILLION PER YEAR! Prop. 15s massive increase in annual property taxes will have disastrous economic impacts for every Californianfrom small businesses and consumers to farmers and homeowners.

Proposition16: ALLOWS DIVERSITY AS A FACTOR IN PUBLIC EMPLOYMENT, EDUCATION, AND CONTRACTING DECISIONS. LEGISLATIVE CONSTITUTIONAL AMENDMENT.

Permits government decision-making policies to consider race, sex, color, ethnicity, or national origin to address diversity by repealing article I, section 31, of the California Constitution, which was added by Proposition 209 in 1996. Proposition 209 generally prohibits state and local governments from discriminating against, or granting preferential treatment to, individuals or groups on the basis of race, sex, color, ethnicity, or national origin in the operation of public employment, education, or contracting.

Argument in Favor:

All of us deserve equal opportunities to thrive with fair wages, good jobs, and quality schools. Despite living in the most diverse state in the nation, white men are still overrepresented in positions of wealth and power in California. Although women, and especially women of color, are on the front lines of the COVID-19 response, they are not rewarded for their sacrifices. Women should have the same chance of success as men.

Argument Against:

REPEAL WOULD BE A STEP BACKWARD Discrimination of this kind is poisonous. It will divide us at a time we desperately need to unite. Politicians want to give preferential treatment to their favorites. They think they can fix past discrimination against racial minorities and women by discriminating against other racial minorities and men who are innocent of any wrongdoing. Punishing innocent people will only cause a never-ending cycle of resentment.

Proposition17: RESTORES RIGHT TO VOTE AFTER COMPLETION OF PRISON TERM. LEGISLATIVE CONSTITUTIONAL AMENDMENT.

Amends state constitution to restore voting rights to persons who have been disqualified from voting while serving a prison term as soon as they complete their prison term. Increased one-time state costs, likely in the hundreds of thousands of dollars, to update voter registration cards and to update voter registration cards and systems.

Argument in Favor:

Proposition 17 is simpleit restores a persons right to vote upon completion of their prison term. When a person completes their prison sentence, they should be encouraged to reenter society and have a stake in their community. Restoring their voting rights does that.

Argument Against:

PROPOSITION 17 WILL ALLOW CRIMINALS CONVICTED OF MURDER, RAPE, SEXUAL ABUSE AGAINST CHILDREN, KIDNAPPING, ASSAULT, GANG GUN CRIMES AND HUMAN TRAFFICKING TO VOTE BEFORE COMPLETING THEIR SENTENCE INCLUDING PAROLE.

Proposition18: AMENDS CALIFORNIA CONSTITUTION TO PERMIT 17-YEAR-OLDS TO VOTE IN PRIMARY AND SPECIAL ELECTIONS IF THEY WILL TURN 18 BY THE NEXT GENERAL ELECTION AND BE OTHERWISE ELIGIBLE TO VOTE. LEGISLATIVE CONSTITUTIONAL AMENDMENT.

The California Constitution currently permits individuals who are at least 18 years old on the date of an election to vote in that election. Increased costs for counties, likely between several hundreds of thousands of dollars and $1 million every two years, to send and process voting materials to eligible registered 17-year-olds

Arguments in Favor:

Follow this link:
Whats on Your Local Ballot? - City News Group, Inc